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Abstract
Background: BRF2 is a transcription factor required for synthesis of a small group of non-coding RNAs by RNA
polymerase III. Overexpression of BRF2 can transform human mammary epithelial cells. In both breast and lung
cancers, the BRF2 gene is amplified and overexpressed and may serve as an oncogenic driver. Furthermore,
elevated BRF2 can be independently prognostic of unfavorable survival. Dietary soy isoflavones increase metastasis
to lungs in a model of breast cancer and a recent study reported significantly increased cell proliferation in breast
cancer patients who used soy supplementation. The soy isoflavone daidzein is a major food-derived phytoestrogen
that is structurally similar to estrogen. The putative estrogenic effect of soy raises concern that high consumption of
soy foods by breast cancer patients may increase tumor growth.
Methods: Expression of BRF2 RNA and protein was assayed in ER-positive or –negative human breast cancer cells after
exposure to daidzein. We also measured mRNA stability, promoter methylation and response to the demethylating
agent 5-azacytidine. In addition, expression was compared between mice fed diets enriched or deprived of isoflavones.
Results: We demonstrate that the soy isoflavone daidzein specifically stimulates expression of BRF2 in ER-positive
breast cancer cells, as well as the related factor BRF1. Induction is accompanied by increased levels of non-coding RNAs
that are regulated by BRF2 and BRF1. Daidzein treatment stabilizes BRF2 and BRF1 mRNAs and selectively decreases
methylation of the BRF2 promoter. Functional significance of demethylation is supported by induction of BRF2 by the
methyltransferase inhibitor 5-azacytidine. None of these effects are observed in an ER-negative breast cancer line, when
tested in parallel with ER-positive breast cancer cells. In vivo relevance is suggested by the significantly elevated levels
of BRF2 mRNA detected in female mice fed a high-isoflavone commercial diet. In striking contrast, BRF2 and BRF1
mRNA levels are suppressed in matched male mice fed the same isoflavone-enriched diet.
Conclusions: The BRF2 gene that is implicated in cancer can be induced in human breast cancer cells by the
isoflavone daidzein, through promoter demethylation and/or mRNA stabilization. Dietary isoflavones may also induce
BRF2 in female mice, whereas the converse occurs in males.
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Background
RNA polymerase (pol) III has the responsibility of syn-
thesizing a variety of short noncoding RNAs such as
tRNAs and the spliceosomal U6 snRNA [1]. Initiation by
pol III requires TFIIIB [1], a transcription factor com-
plex with at least two forms in mammalian cells [2, 3].
Gene-internal pol III promoters, such as those found in
tRNA genes, require TFIIIB composed of TBP, BDP1
and BRF1 subunits, whereas gene-external pol III pro-
moters, as exemplified by U6 genes, require TFIIIB con-
taining TBP, BDP1 and BRF2 [1]. Aberrant pol III
transcription is a feature of many tumor types [4]. This
reflects, in part, the fact that TFIIIB is strongly regulated
by pathways involving oncogenes and tumor suppressors
[4, 5]. For example, MYC [6] and the MAP kinase ERK [7]
bind to TFIIIB and stimulate its activity, whereas an array of
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tumor suppressors inhibit TFIIIB activity [8], either directly
or indirectly, including BRCA1 [9], PTEN [10, 11], p53 [12],
and the RB family [13].
The BRF2 subunit of TFIIIB is encoded by an onco-
gene at 8p12 that is frequently amplified and overex-
pressed in breast cancers and lung squamous cell
carcinomas (SqCC) [14–20, 21]. BRF2 drives the 8p12
amplification in SqCC [22]. Its overexpression stimulates
proliferation and saturation density of human bronchial
epithelial cells, whereas its knockdown specifically sup-
presses proliferation and anchorage-independent growth
of SqCC cells with 8p12 amplification [22]. Copy num-
ber increases and overexpression of BRF2 are apparent
in most pre-invasive bronchial carcinomas in situ, with
minimal staining in benign lesions [22]. BRF2 induction
was therefore proposed as an early event in development of
lung SqCC, that might serve as a marker and/or therapeutic
target [22]. Subsequent independent studies reported ele-
vated BRF2 protein in lung and esophageal SqCC, where
high BRF2 was independently prognostic of unfavorable
survival for both lung (P = 0.007) and esophageal (P =
0.009) SqCC [23, 24]. BRF2 overexpression may also be an
oncogenic driver in some breast cancers and human mam-
mary epithelial cells can be transformed by transfection of
the BRF2 gene [15]. Analysis of published datasets, using
the Web-based Oncomine platform, reveals that BRF2 was
amongst the top 1 % of genes overexpressed in a study [25]
of 154 invasive breast carcinomas (p = 3.53E-10), whilst a
larger study of over two thousand breast samples [26] con-
firmed BRF2 overexpression in several tumor subgroups,
with invasive ductal breast carcinomas the most significant
(p = 2.17E-21). The cBioPortal cancer genomics database
[27–29] reveals amplification of the BRF2 gene in 12 % of
825 tumors in the Breast Invasive Carcinoma study (TCGA,
Nature 2012) [30].
The chemopreventive polyphenol EGCG, enriched in
green tea, specifically decreases TFIIIB activity in cer-
vical cancer cells [31]. The polyphenols genistein and
daidzein are isoflavone components of soybeans, a major
crop in the United States and globally [32]. These soy
isoflavones are major food-derived phytoestrogens that
are structurally similar to estrogen with the capacity to
weakly bind to estrogen receptors (ERs) [33]. The puta-
tive estrogenic effect of soy raises the concern that high con-
sumption of soy foods by breast cancer patients and/or
women at high risk for breast cancer may increase estrogen-
dependent breast tumor growth [34]. A recent study re-
ported a significant increase in cell proliferation in breast
cancer patients who used soy supplementation [35]. Dietary
soy isoflavones increase metastasis to lungs in an experimen-
tal model of breast cancer [36]. These data prompted us to
investigate if the soy isoflavone daidzein regulates TFIIIB.
We found that 10 uM daidzein stimulates expression of the
TFIIIB subunits BRF1 and BRF2 in ER-positive breast cancer
cells, as well as pol III products U6 snRNA and tRNAi
Met.
Daidzein treatment stabilizes BRF2 and BRF1 mRNAs and
raises levels of their protein products. It also triggers selective
demethylation of the BRF2 promoter. These effects are not
seen in an ER-negative breast cancer line. An isoflavone-
enriched diet also induces BRF2 in female mice, but has the
opposite effect inmales. These in vitro and in vivo data suggest
that dietary isoflavones differentially regulate TFIIIB expres-
sion, an important observation given the evidence that BRF2
can drive tumorigenesis and is predictive of poor prognosis.
Methods
Cell lines and daidzein treatment
MCF-7 and MDA-MB-231 cells were obtained from the
American Type Culture Collection (Rockville, MD). Cells
were cultured in DMEM supplemented with FBS (5 % v/
v), nonessential amino acids (100 mM), L-glutamine
(5 mM), streptomycin (100 μg/ml), and penicillin (100
units/ml); all from BioWhittaker, Walkersville, MD. Cells
were grown at 37 °C in a humidified atmosphere of 95 %
air and 5 % CO2 as previously described [37, 38]. Daidzein
(Sigma) treatments are as described in figure legends.
5-Azacytidine treatment
Asynchronous MCF-7 and MDA-MB-231 cells were
plated at 1 × 104 cell/well in 6-well plates. After 24 h,
cells were treated with 5 μM 5-azacytidine (Sigma) for
24, 48 and 72 h. At each time point, total RNA was col-
lected using RNeasy total RNA isolation kit (Qiagen), ac-
cording to the manufacturer's protocol and cDNA
subsequently prepared to be used in qRT-PCRassays.
Quantitative reverse transcription PCR (qRT-PCR)
Total RNA was extracted from cancer cell lines using the
RNeasy total RNA isolation kit (Qiagen), according to the
manufacturer's protocol and qPCR was performed using di-
luted cDNA from treated breast cancer cells and SsoAd-
vanced™ Universal SYBR® Green Supermix (BioRad). Gene
specific primers include: BRF2-forward, 5’-CAG AAG TGG
AGA CCC GAG AG-3’; BRF2-reverse, 5’-CAG GGA GGG
TTA GGG ACA CT-3’; BRF1-forward, 5’-GGC ATT GAT
GAC CTG GAG AT-3’; BRF1-reverse, 5’-ACC AGA GGC
CTC AAC CTT TT-3’; BDP1-forward, 5’-TGG AAG AAG
CTG GAA GGA GA-3’; BDP1-reverse, 5’-TTC CTC AAT
GGC ATC AAT CA-3’; TBP-forward, 5’-CGG CTG TTT
AAC TTC GCT TC-3’; TBP reverse, 5’-CTG TTG TTG
TTG CTG CTG CT-3’; U6-forward, 5’-GGT CGG GCA
GGA AAG AGG GC-3’; U6-reverse, 5’- GCTAAT CTT
CTC TGT ATC GTT CC-3’; tRNAi
Met-forward, 5’- CTG
GGC CCA TAA CCC AGA G-3’; tRNAi
Met-reverse,
5’-TGG TAG CAG AGG ATG GTT TC-3’; GAPDH-
forward, 5’- TCCACCACCCTGTTGCTGTA-3’; GAPDH-
reverse, 5’- ACC ACA GTC CAT GCC ATC AC-3’;
RPS13-forward, 5’-GTT GCT GTT CGA AAG CAT CTT
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G-3’; RPS13-reverse, 5’-AAT ATC GAG CCA AAC GGT
GAA-3’; actin β-forward, 5’-TAG CGG GGT TCA CCC
ACA CTG TGC CCC A-3’; actin β-reverse, 5’- CTA GAA
GCA TTT GCG GTG GAC CGA TGG A-3’. Real time
quantitative PCR reactions were carried out using the Bio-
Rad CFX Connect System. The ΔΔCt method was
employed for each gene tested as noted in figures
using GAPDH and RPS13 expression levels for
normalization. Meta-analysis of data using one-way
ANOVA with a Tukey post-test with a 95 % confi-
dence interval (GraphpadPrism3.03, San Diego
California USA); * = p <0.05; ** = p < 0.01; *** = p < 0.001.
Western blot analysis
Total cellular protein was extracted using Cytobuster
Protein Extraction Reagent (Merck Millipore; 71009).
Proteins were fractionated by SDS-PAGE and trans-
ferred to nitrocellulose membranes, which were incu-
bated overnight with antibodies against BRF1 (Bethyl
Laboratories; A301-228A), BRF2 and actin (Santa Cruz
Biotechnology; sc-390312 and sc-1615). Membranes
were then incubated with HRP-conjugated anti-goat
(Dako; P0449) anti-rabbit and anti-mouse (Cell Signal-
ing; 7074 and 7076) IgG for 1 h. Bands were visualized
using the enhanced chemiluminescence method.
Methylation analysis
Promoters were analyzed using MethPrimer [39] to
identify potential CpG islands. NEBcutter V2.0 [40] was
used to identify methylation sensitive restriction enzyme
(MSRE) sites sensitive within promoter sequences. Gen-
omic DNA was isolated from MCF-7 and MD-MB-231
cancer cells using DNeasy Blood & Tissue Kit (Qiagen)
using the manufacturer’s protocol. Restriction enzymes
AciI, AscI, BanI, BfuAI, BsrFI, BsrBI, BseYI, BfuAI,
BspEI, Cac81, FspI, NciI, NruI (New England Biolabs)
and HpyCH4III/Taal (Fermentas) were used. Restriction
digestions were then analyzed by real time PCR using
Universal SYBR Green (BioRad) and primers spanning
the promoters regions and primers spanning the pro-
moters regions (BRF2-forward, 5’-GGC CTC CAA AAG
CGT T-3’; BRF2-reverse, 5’-AGC TGG CTC TGC GAA
TAG T-3’; BRF1-forward, 5’-GGG GTT GGG TCC
CAG GTC GC-3’; BRF1-reverse, 5’-GTC CTC CAG
CAC TGA GCC GC-3’; U6-forward, 5’- AAG TAT TTC
GAT TTC TTG GC-3’; U6-reverse, 5’- AAT ATG GAA
CGC TTC ACG-3’; tRNAi
Met-forward, 5’-TAG ATA
GCA GAG TGG CGC A-3’; tRNAi
Met-reverse, 5’-AAC
TCC GAT AGC AGA GGA TG-3’). Results were quanti-
fied using the ΔΔCt method and normalized to RPS13
expression levels. Data presented are average of three in-
dependent experiments. Statistical analysis was per-
formed using one-way ANOVA with a Tukey’s post-test
with a 95 % confidence interval (Graphpad Prism 3.03);
* = p <0.05; ** = p < 0.01; *** = p < 0.001.
mRNA stability of the BRF1 and BRF2 genes
The mRNA stability of BRF1 and BRF2 mRNA was de-
termined following actinomycin D treatment. Actinomy-
cin D was added to a final concentration of 5 μg/ml to
block transcription [41]. At 0, 4, 8, 12 and 24 h post-
actinomycin D treatment, the cells were harvested, and
mRNA was quantified by qRT-PCRas described above.
Data show relative expression values at time points indi-
cated with control untreated sample set to 1 at 0 h post-
actinomycin D treatment.
ELISA
BRF2 protein levels were measured from untreated and
daidzein treated MCF-7 and MD-MB-231 cells using a
human BRF2 ELISA kit (MyBioSource) as per the manu-
facturer’s protocol. Data presented are average of four
independent experiments. Statistical analysis was per-
formed using one-way ANOVA with a Tukey’s post-test
with a 95 % confidence interval (Graphpad Prism 3.03);
* = p <0.05; ** = p < 0.01; *** = p < 0.001.
Animals and isoflavone treatment
Female and male C57BL/6 J mice were purchased from
Taconic Farms (Germantown, New York). Mice were
housed 4 per cage in a temperature-controlled St. John’s
University Animal Care Facility with alternating 12:12 h
light–dark cycles, with ad libitum access to water and
commercial Purina 5001 or 5 K96 chows (Fig. 7), as ap-
proved in its entirety by SJU IACUC (SJU Protocol num-
ber 1831.0). Mice were numbered with permanent
marker identification, and acclimated to animal pent-
house for 72 h prior to start of experiment. Mice were
treated for a total of three weeks and monitored daily
for signs of stress. Weekly tail bleeds and a terminal car-
diac puncture bleed were collected and analyzed for
TFIIIB levels via qRT-PCR.
Results
Daidzein induces BRF1, BRF2 and pol III transcript
expression in MCF-7 breast cancer cells
Human breast cancer cell lines were treated for 48 h
with daidzein and qRT-PCRwas used to assay expression
of mRNAs encoding the subunits of TFIIIB. The
mRNAs encoding BRF1 and BRF2 were both found to
be induced significantly in ER-positive MCF-7 cells (p <
0.001 and p < 0.01, respectively; Fig. 1a). This response is
selective and not shown by the mRNAs encoding TBP and
BDP1, the other TFIIIB subunits. Furthermore, none of the
TFIIIB mRNAs showed significant responses to daidzein in
ER-negative MDA-MB-231 cells, under these conditions
(Fig. 1b). The induction of BRF1 and BRF2 mRNAs in
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MCF-7 cells is translated into a corresponding increase in
the protein products, as shown by western blotting (Fig. 2a).
As with the mRNA, protein expression does not respond in
MDA-MB-231 cells (Fig. 2b). Quantitative analysis by
ELISA established that BRF2 protein induction in MCF-7
cells is 2.4-fold with 3 μM daidzein and 4.2-fold with
10 μM daidzein (Fig. 2c). As observed by western, no sig-
nificant change in BRF2 levels was detected by ELISA with
MDA-MB-231 cells (Fig. 2d). The uninduced level of BRF2
is higher in MDA-MB-231 than MCF-7 cells (1.4-fold ele-
vated by quantitative ELISA), consistent with a previously
published report [42], which showed that BRF2 mRNA is
expressed at higher levels in MDA-MB-231 cells than in
MCF-7 cells. However, it is unlikely that BRF2 has reached
a saturation point in untreated MDA-MB-231 cells that
would preclude further induction.
If the observed induction of BRF1 and BRF2 is func-
tionally significant, we would expect to see changes in
expression of pol III products that depend upon these
subunits for their transcription. Indeed, both U6 snRNA,
dependent on BRF2, and tRNAi
Met, requiring BRF1, show
significant induction in MCF-7 cells by 10 μM daidzein
(Fig. 3a). As with BRF1 and BRF2, neither of these pol
III transcripts is induced when MDA-MB-231 cells are
Fig. 1 Daidzein induces BRF1 and BRF2 mRNA specifically in MCF-7 breast cancer cells. MCF-7 (a) and MDA-MB-231 (b) cells were treated with 0,
3 or 10 μM daidzein for 48 h. BRF2, BRF1, BDP1 and TBP mRNA expression was then analysed by qRT-PCRusing the ΔΔCt method with RPS13 ex-
pression levels as a reference for normalization. Meta-analysis of three independent experiments performed in triplicate was completed using
one-way ANOVA with a Tukey’s post-test with a 95 % confidence interval (Graphpad Prism 3.03); * = p <0.05; ** = p < 0.01; *** = p < 0.001
Fig. 2 Daidzein induces BRF1 and BRF2 protein specifically in MCF-7 cells. MCF-7 (a) and MDA-MB-231 (b) cells were treated with 0 or 3 μM daid-
zein for 48 h and then analysed for expression of BRF1, BRF2 and actin proteins by western blot. Quantification of BRF2 protein expression in (c)
MCF-7 and (d) MDA-MB-231 cells treated with daidzein was achieved by ELISA. Data presented are average of four independent experiments.
Statistical analysis was performed using one-way ANOVA with a Tukey’s post-test with a 95 % confidence interval (Graphpad Prism 3.03); * = p
<0.05; ** = p < 0.01; *** = p < 0.001
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treated in the same way (Fig. 3b). As pol III activity is
generally coupled to cell proliferation, we tested if daid-
zein has a mitogenic effect under our assay conditions.
However, cell viability assays provided no evidence of
enhanced proliferation when either cell line was exposed
to 10 μM daidzein (Figs. 3c and d); indeed, significant
suppression was observed after 72 h, in agreement with
previous studies noting daidzein treatments greater than
1 μM inhibit breast cancer cell proliferation [43]. The se-
lective induction of U6 snRNA and tRNAi
Met therefore
appears not to reflect a mitogenic response, but corre-
lates with increases in BRF1 and BRF2.
Daidzein decreases methylation of the BRF2 promoter
specifically in MCF-7 cells
There are a number of published studies describing epi-
genetic regulation of gene expression by dietary polyphe-
nols in prostate and breast cancer cell lines [44, 45]. We
therefore investigated whether daidzein influences DNA
methylation of the BRF1 and BRF2 promoter regions.
Treatment of MCF-7 cells with 10 μM daidzein signifi-
cantly decreased methylation of four restriction sites in
the BRF2 promoter (Fig. 4a). The same treatment had
minimal effect on the methylation status of several re-
striction sites within the BRF1 promoter (Fig. 4b). The
minimal response of BRF1 indicates that the effect of
daidzein on BRF2 promoter methylation is selective. Fur-
ther evidence of specificity is provided by analysis of U6
and tRNAi
Met genes, where DNA methylation is un-
changed in response to daidzein (Figs. 4c and d). Local-
ized demethylation of the BRF2 promoter was also
observed when MDA-MB-231 cells were treated with
daidzein, but the response was less marked than in
MCF-7 cells and only one site showed a statistically-
significant change at the 10 μM dose (Fig. 4e). In un-
treated cells, the BRF2 was much less heavily methylated
in MDA-MB-231 than in MCF-7 (Fig. 4f ), which may
explain its higher expression in the former (Fig 2. and
[42]).
If demethylation of promoter DNA can influence tran-
scription of the BRF2 gene, then treatment with the
methylation inhibitor 5-azacytidine might be predicted
to induce expression. Indeed, BRF2 mRNA levels were
elevated within 48 h of adding 5-azacytidine to MCF-7
cells, along with promoter demethylation (Figs. 5a and
b). This response was specific, as it was not shown by
BRF1 mRNA when assayed in parallel (Fig. 5c). Further-
more, the same treatment failed to induce either BRF1
or BRF2 in MDA-MB-231 cells (Figs. 5d and e). These
data suggest that BRF2 promoter activity may be sensi-
tive to DNA methylation, which responds to daidzein in
MCF-7 cells.
Fig. 3 Daidzein induces U6 snRNA and tRNAi
Met specifically in MCF-7 cells without inducing proliferation. MCF-7 (a) and MDA-MB-231 (b) cells
were treated with 0, 3, 10 μM daidzein for 48 h. U6 snRNA and tRNAiMet expression was then analysed by qRT-PCRusing the ΔΔCt method with
RPS13 expression levels as a reference for normalization. Meta-analysis of three independent experiments performed in triplicate was completed
using one-way ANOVA with a Tukey’s post-test with a 95 % confidence interval (Graphpad Prism 3.03); * = p <0.05; ** = p < 0.01; *** = p < 0.001.
CellTiter-Glo® (Promega) was used to count MCF- 7 (c) and MDA-MB-231 cells (d) after 24, 48 and 72 h treatment with 0, 3 or 10 μM daidzein, as
indicated. Each dose and time point was performed in triplicate. MDA-MD-231 cell proliferation significantly decreased with 10 μM daidzein after
48 h (p < 0.05) and 72 h (p < 0.01) treatment. MCF-7 cell proliferation significantly decreased at 48 h (p < 0.01) with 3 μM daidzein treatment. At
10 μM daidzein treatment cell proliferation was significantly inhibited in MCF-7 cells at 24 h (p < 0.05), 48 h (p < 0.01) and 72 h (p < 0.01)
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Fig. 4 (See legend on next page.)
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Daidzein increases stability of BRF1 and BRF2 mRNAs in
MCF-7 cells
The 3’-untranslated regions (3’-UTR) of BRF1 and BRF2
mRNAs are AU-rich, which may influence their stability
[42]. Various classes of polyphenols have been shown to
post-transcriptionally regulate levels of mRNA contain-
ing AU-rich elements by raising expression of RNA
binding proteins [46–49]. To test if daidzein stabilizes
BRF mRNAs, as a potential mechanism of induction, we
treated MCF-7 cells with the transcription inhibitor
Fig. 5 Azacytidine induces demethylation and expression of BRF2 selectively in MCF-7 cells. a, b, c MCF-7 and (d, e) MDA-MB-231 cells were
treated with 5 μM 5-Azacytidine for 24, 48 and 72 h. Post-treatments, total RNA was isolated and analyzed by qRT-PCRfor expression of (a, d)
BRF2 and (c, e) BRF1 mRNAs. The ΔΔCt method with GAPDH and RPS13 expression levels was used as a reference for normalization. Meta-
analysis of two independent experiments performed in triplicate was completed using one-way ANOVA with a Tukey’s post-test with a 95 %
confidence interval (Graphpad Prism 3.03); * = p <0.05; ** = p < 0.01; *** = p < 0.001. (b) Genomic methylation of BRF2 promoter DNA in MCF-7
cells was analyzed with methylation-sensitive restriction enzymes, as in Fig. 4a
(See figure on previous page.)
Fig. 4 Daidzein changes DNAmethylation at the BRF2 promoter specifically. CpGmethylation- sensitive restriction enzymes cut sites are shown. Transcription
start site (TSS) is indicated by +1. MethPrimer programwas used to predict the location of CpG islands within the BRF2 (402–556 bp) and BRF1 (50–910 bp)
promoters, as indicated by black arrow. Black bars denote the binding sites for primers used in themethylation profile analysis. a-dMCF-7 and (e) MDA-MB-231
cells were treatedwith 0, 3, 10 μMdaidzein for 48 h. The genomic DNAwas harvested and digestedwithmethylation-sensitive restriction enzymeswith cut
sites within the promoter, noted on BRF2 and BRF1 promoter schematic, and as a negative control onemethylation sensitive enzymewith no recognition sites
in the promoter was used. BspEI and BsRFI do not have recognition sites in BRF2 and BRF1 promoters, respectively. The digestion profile was then analyzed by
qPCR using primers spanning the BRF2 (a, e, f) and BRF1 (b) promoter regions, U6 (c) and tRNAi
Met (d) genes. DNAmethylation levels were calculated usingΔΔCt
methodwith RPS13 expression levels used as a reference for normalization. Data presented are average of three independent experiments. Statistical analysis was
performed using one-way ANOVA a Tukey’s post-test with a 95% confidence interval (Graphpad Prism 3.03); * = p<0.05; ** = p< 0.01; *** = p< 0.001
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actinomycin D [41] and monitored mRNA decay using
qRT-PCR. Although 10 μM daidzein was unable to pre-
vent the turnover of BRF mRNAs by 24 h, it prevented
degradation of both BRF2 (p < 0.01; Fig. 6a) and BRF1
(p < 0.05; Fig. 6b) for 12 h after transcription inhibition.
This effect is specific, as mRNA encoding ribosomal
protein S13 (RPS13) decayed with similar kinetics in the
presence or absence of daidzein, when assayed in parallel
(Fig. 6c). The selective stabilization of BRF mRNAs of-
fers a potential explanation for the increased expression
seen when MCF-7 cells are exposed to 10 μM daidzein.
Additional mechanisms may also be involved, such as
demethylation of the BRF2 promoter (Fig. 4b).
Commercial rodent chow differentially regulates BRF1
and BRF2 in a sex-dependent manner
Purina 5001 is a chow that is commonly fed to labora-
tory rodents and contains high levels of both daidzein
and genistein, the two major isoflavone components of
soybeans [50]. Our observations with daidzein in cul-
tured cells prompted us to investigate if BRF expression
is elevated in mice fed a diet enriched in these isofla-
vones. RNA was isolated from the blood of mice main-
tained on either Purine 5001 or the isoflavone-free
casein-based Purina 5 K96 chow. Significantly elevated
BRF2 expression was found in female mice with the high
isoflavone Purina 5001 diet (Fig. 7a). In striking contrast,
the opposite was seen in males, where BRF2 expression
was significantly lower with high isoflavones relative to
the isoflavone-free diet (Fig. 7b). BRF1 was also sup-
pressed in males fed the high isoflavone Purina 5001
chow, but was unaffected in females. No statistically sig-
nificant changes were found in the other TFIIIB sub-
units, TBP and BDP1. These in vivo data suggest that
male and female C57BL/6 J mice respond differently to
dietary sources of isoflavones and these differences are
measurable in the blood. They emphasize the import-
ance of taking into account both gender and diet in
mouse models of cancer.
Discussion
Breast cancer is the leading cause of cancer-related
deaths in females in developing countries and the sec-
ond leading cause in developed countries [51, 52]. It has
been estimated that there will be approximately 1.7 mil-
lion new cases of breast cancer in 2020, a 26 % increase
from current incidence rates, mostly due to the increase
in new cases in the developing world [53]. As diet is
known to influence the incidence of breast cancer [54],
identifying the impact of specific foods is imperative. Soy
has been studied extensively for its anti-cancer properties,
but the epidemiological results have been contradictory, in
part because soy can regulate gene expression via estro-
gen- dependent and independent pathways. We therefore
investigated the molecular effects of the isoflavone daid-
zein in both ER-positive and ER-negative cancer cells. We
observed clear effects in the former that were not seen in
the latter. Specifically, daidzein raises expression of BRF2
and BRF1 in MCF-7 cells, as well as pol III transcripts that
depend on these TFIIIB subunits for their synthesis. It is
noteworthy that another polyphenol, EGCG that is
enriched in green tea, also affects expression of BRF1 and
BRF2 selectively, but in this case elicits an inhibitory ef-
fect, in keeping with its anti-cancer activity [31].
Induction of BRF2 and BRF1 by daidzein may be ex-
plained by stabilization of their respective mRNAs, al-
though additional effects might also contribute. For
example, we also observed demethylation of the BRF2
promoter that might result in a transcriptional response.
How the polyphenol produces these effects remains to
be established. A clear possibility is that the ER is in-
volved, either directly or indirectly, as this can be weakly
bound by daidzein [33]. Indeed, ER has been shown to
bind directly to the BRF1 promoter in MCF-7 cells [55]
and 17β-estradiol has been shown to induce tRNA synthe-
sis [56]. Those studies did not investigate BRF2 or its target
genes, such as U6. Circumstantial evidence in support of
ER involvement is provided by the differential response in
ER-positive MCF-7 and ER-negative MDA-MB-231 cells in
Fig. 6 Daidzein increases stability of BRF1 and BRF2 mRNAs selectively in MCF-7 cells. MCF-7 cells were treated with 5 μg/ml of actinomycin D, ei-
ther alone (white bars) or with 10 μM daidzein (black bars) for 24 h. The cells were then harvested at 4, 8, 12 and 24 h. The RNA was extracted
and analyzed by qRT-PCRfor levels of (a) BRF2, (b) BRF1, (c) RPS13, and actin β mRNAs. ΔΔCt method with RPS13 and actin β expression levels
were calculated for assay normalization. Data presented are average of three independent experiments. Statistical analysis was performed using
one-way ANOVA with a Tukey’s post-test with a 95 % confidence interval (Graphpad Prism 3.03); * = p <0.05; ** = p < 0.01; *** = p < 0.001
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culture, and the gender-specificity of induction in mice.
However, further studies will be required to establish if ER
mediates the observed effects. In terms of the current study,
we consider the crucial finding to be that physiologically
relevant doses of a common dietary compound can stimu-
late expression of a gene with established oncogenic proper-
ties. This raises concerns for women consuming soy.
It remains to be determined how BRF2 exerts onco-
genic effects, although the obvious possibility is through
transcriptomic changes, given its well-established func-
tion as a transcription factor. Genome-wide analyses
showed that BRF2 has a highly restricted set of target
genes [57], all encoding short pol III-dependent noncod-
ing RNAs. In addition to U6 snRNA, these include 7SK
RNA, which regulates transcription of protein-coding
genes by inhibiting P-TEFb [58–60], and hY RNAs,
which promote DNA replication [61]. The hY RNAs are
commonly overexpressed in tumors [62, 63]. For ex-
ample, hY1 is overexpressed ~13-fold in lung, prostate
and other cancers (P = 9.7 × 10−26) and its knockdown
inhibits proliferation of lung and prostate cell lines [62].
As a key component of spliceosomes, U6 snRNA is an
essential BRF2-dependent product. It was consistently
detected at elevated levels in sera from 140 breast cancer
patients, relative to 115 healthy age-matched controls
[64]. U6 was also the most strongly upregulated (P <
0.0001; FDR <0.001) non-coding RNA in serum from 75
glioblastoma multiforme patients, relative to matched
healthy controls [65]. MicroRNAs are widely believed to
have considerable potential as biomarkers, but U6 out-
performed all 381 miRNAs tested in this study [65]. It
has also been suggested that BRF2 might serve as a bio-
marker, given its early induction in development of lung
SqCC [22], where high BRF2 is independently prognostic
(P = 0.007) of unfavourable survival [24], as also reported
(P = 0.009) for oesophageal SqCC [23]. Our demonstra-
tion that BRF2 levels can be monitored in mouse serum
provides initial evidence that a non-invasive test is prac-
tical for this potential biomarker.
Conclusions
This study demonstrates, both in vitro and in vivo, that
a common soy isoflavone, at dietary concentrations, can
influence expression of BRF2 and BRF1, essential com-
ponents of the pol III-specific transcription factor
TFIIIB. The response may involve an epigenetic compo-
nent and gender-dependence in mice. Its importance is
suggested by recent evidence that BRF2 can be onco-
genic and prognostic of poor survival.
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